Cancer is a major cause of death worldwide. MET tyrosine kinase receptor [MET, c-MET,
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …

Uncommon Epidermal Growth Factor Receptor (EGFR) mutations represent a distinct and
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Purpose: Patient-derived organoids (PDO) of lung cancer has been recently introduced,
reflecting the genomic landscape of lung cancer. However, clinical relevance of advanced …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

Recent changes in lung cancer care, including new approvals in first line and the
introduction of high-throughput molecular technologies in routine testing led us to question …

Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …

Background The clinicopathologic characteristics, acquired resistance patterns, and
outcomes among patients with atypical EGFR mutations and HER2 alterations remain …

Lung cancer is a leading cause of cancer-related deaths worldwide. Epidermal growth factor
receptor (EGFR) driver mutations are crucial for treatment decisions for patients with non …